Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phibro Animal Health (PAHC) Cash & Equivalents: 2013-2025

Historic Cash & Equivalents for Phibro Animal Health (PAHC) over the last 13 years, with Sep 2025 value amounting to $72.8 million.

  • Phibro Animal Health's Cash & Equivalents rose 40.38% to $72.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $72.8 million, marking a year-over-year increase of 40.38%. This contributed to the annual value of $68.0 million for FY2025, which is 3.65% down from last year.
  • According to the latest figures from Q3 2025, Phibro Animal Health's Cash & Equivalents is $72.8 million, which was up 6.95% from $68.0 million recorded in Q2 2025.
  • Phibro Animal Health's 5-year Cash & Equivalents high stood at $76.3 million for Q3 2022, and its period low was $33.0 million during Q4 2023.
  • In the last 3 years, Phibro Animal Health's Cash & Equivalents had a median value of $51.8 million in 2024 and averaged $54.1 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first tumbled by 51.81% in 2023, then soared by 103.44% in 2024.
  • Phibro Animal Health's Cash & Equivalents (Quarterly) stood at $63.4 million in 2021, then grew by 7.95% to $68.4 million in 2022, then plummeted by 51.81% to $33.0 million in 2023, then spiked by 103.44% to $67.1 million in 2024, then surged by 40.38% to $72.8 million in 2025.
  • Its Cash & Equivalents was $72.8 million in Q3 2025, compared to $68.0 million in Q2 2025 and $60.4 million in Q1 2025.